{
    "clinical_study": {
        "@rank": "38618", 
        "brief_summary": {
            "textblock": "Despite the implementation of modern public health interventions, 1 in 5 adults in the\n      United States are either current or former smokers and remain at risk for the development of\n      chronic lung diseases.  It is unknown how or why any one individual smoker can develop a\n      wide range of lung diseases including chronic obstructive lung disease and/or pulmonary\n      fibrosis.  The purpose of this protocol is to collect clinical data, blood, urine, and\n      bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic\n      clinical profiles that correspond to divergent pathways in the expression of such proteins\n      as the transforming growth factor-beta1 (TGF- <=1).  The information generated from this\n      study will provide insight into the pathogenesis of smoking-related lung injury and\n      potentially allow for the development of early therapeutic interventions...."
        }, 
        "brief_title": "Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Fibrosis", 
            "Lung Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Lung Diseases", 
                "Pulmonary Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Despite the implementation of modern public health interventions, 1 in 5 adults in the\n      United States are either current or former smokers and remain at risk for the development of\n      chronic lung diseases.  It is unknown how or why any one individual smoker can develop a\n      wide range of lung diseases including chronic obstructive lung disease and/or pulmonary\n      fibrosis.  The purpose of this protocol is to collect clinical data, blood, urine, and\n      bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic\n      clinical profiles that correspond to divergent pathways in the expression of such proteins\n      as the transforming growth factor-beta1 (TGF- <=1).  The information generated from this\n      study will provide insight into the pathogenesis of smoking-related lung injury and\n      potentially allow for the development of early therapeutic interventions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA\n\n        For subjects with lung diseases:\n\n          -  Men and women age 40-80 years\n\n          -  Smokers with greater than or equal to 10 pack-year history of ever-smoking\n\n        EXCLUSION CRITERIA\n\n        For subjects with lung diseases:\n\n        Subjects will be excluded from the study if they meet one or more of the following\n        criteria:\n\n          -  Subjects who are under the age of 40 or over 80 years old\n\n          -  Women who are pregnant or lactating\n\n          -  Have known allergies to lidocaine or medications used for moderate sedation\n\n          -  Active coronary artery disease\n\n          -  Cerebral-vascular accident within the past 12 months\n\n          -  Active anticoagulation\n\n          -  Active infections\n\n          -  Cancer, or a history of cancer within the previous 5 years of screening (other than\n             adequately treated cutaneous basal cell, squamous cell carcinoma, or carcinoma in\n             situ of the uterine cervix with no evidence of recurrence).\n\n          -  Poorly controlled chronic diseases\n\n          -  Unable to provide consent\n\n          -  Impaired renal function (including dialysis)\n\n          -  Contraindications to MRI scan including:\n\n               -  electrical implants such as cardiac pacemakers or perfusion pumps\n\n               -  ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,\n                  artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos\n                  near the eye, or steel implants\n\n               -  ferromagnetic objects such as jewelry or metal clips in clothing\n\n               -  pre-existing medical conditions, including a likelihood of developing seizures\n                  or anxiety disorders such as claustrophobia, panic attacks or any psychiatric\n                  disorder\n\n        INCLUSION CRITERIA\n\n        For Non-Smoking Controls\n\n          -  Men and women age 40-80 years\n\n          -  No prior history of smoking (this is a non-smoking cohort)\n\n        EXCLUSION CRITERIA\n\n        For Non-Smoking Controls\n\n          -  Subjects who are under the age of 40 or over 80 years old\n\n          -  Women who are pregnant or lactating\n\n          -  Have known allergies to lidocaine or medications used for moderate sedation\n\n          -  Active coronary artery disease\n\n          -  Cerebral-vascular accident within the past 12 months\n\n          -  Active anticoagulation\n\n          -  Active infections\n\n          -  Cancer, or a history of cancer within the previous 5 years of screening (other than\n             adequately treated cutaneous basal cell, squamous cell carcinoma, or carcinoma in\n             situ of the uterine cervix with no evidence of recurrence).\n\n          -  Poorly controlled chronic diseases\n\n          -  Unable to provide consent\n\n          -  Impaired renal function (including dialysis)\n\n          -  Contraindications to MRI scan including:\n\n               -  electrical implants such as cardiac pacemakers or perfusion pumps\n\n               -  ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,\n                  artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos\n                  near the eye, or steel implants\n\n               -  ferromagnetic objects such as jewelry or metal clips in clothing\n\n               -  pre-existing medical conditions, including a likelihood of developing seizures\n                  or anxiety disorders such as claustrophobia, panic attacks or any psychiatric\n                  disorder\n\n        INCLUSION CRITERIA\n\n        For Smoking Controls\n\n          -  Men and women age 40-80 years\n\n          -  Subjects who have a prior smoking history\n\n        EXCLUSION CRITERIA\n\n        For Smoking Controls\n\n          -  Subjects who are under the age of 40 or over 80 years old\n\n          -  Women who are pregnant or lactating\n\n          -  Have known allergies to lidocaine or medications used for moderate sedation\n\n          -  Active coronary artery disease\n\n          -  Cerebral-vascular accident within the past 12 months\n\n          -  Active anticoagulation\n\n          -  Active infections\n\n          -  Cancer, or a history of cancer within the previous 5 years of screening (other than\n             adequately treated cutaneous basal cell, squamous cell carcinoma, or carcinoma in\n             situ of the uterine cervix with no evidence of recurrence).\n\n          -  Poorly controlled chronic diseases\n\n          -  Unable to provide consent\n\n          -  Impaired renal function (including dialysis)\n\n          -  Contraindications to MRI scan including:\n\n               -  electrical implants such as cardiac pacemakers or perfusion pumps\n\n               -  ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,\n                  artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos\n                  near the eye, or steel implants\n\n               -  ferromagnetic objects such as jewelry or metal clips in clothing\n\n               -  pre-existing medical conditions, including a likelihood of developing seizures\n                  or anxiety disorders such as claustrophobia, panic attacks or any psychiatric\n                  disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "223", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055222", 
            "org_study_id": "140049", 
            "secondary_id": "14-H-0049"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Smoking", 
            "Idiopathic Pulmonary Fibrosis"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2014-H-0049.html"
        }, 
        "location": {
            "contact": {
                "email": "prpl@mail.cc.nih.gov", 
                "last_name": "For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)", 
                "phone": "800-411-1222", 
                "phone_ext": "TTY8664111010"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease", 
        "overall_contact": {
            "email": "mhaughey@nhlbi.nih.gov", 
            "last_name": "Mary Haughey, R.N.", 
            "phone": "(301) 496-3632"
        }, 
        "overall_contact_backup": {
            "email": "mossj@nhlbi.nih.gov", 
            "last_name": "Joel Moss, M.D.", 
            "phone": "(301) 496-1597"
        }, 
        "overall_official": {
            "affiliation": "National Heart, Lung, and Blood Institute (NHLBI)", 
            "last_name": "Joel Moss, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD.", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "reference": [
            {
                "PMID": "19910909", 
                "citation": "Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1227-32."
            }, 
            {
                "PMID": "20935110", 
                "citation": "Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8. Review."
            }, 
            {
                "PMID": "17507545", 
                "citation": "Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055222"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Demonstrate divergent regulation of TGF-B1 related molecular pathways in smokers with ILA and IPF patients when compared to patients with COPD.", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}